ASND vs. HALO: Ascendis Pharma vs. Halozyme Therapeutics Stock Comparison
How do Ascendis Pharma (ASND) and Halozyme Therapeutics (HALO) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Ascendis Pharma (ASND) and Halozyme Therapeutics (HALO) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | ASND | HALO |
|---|---|---|
| Name | Ascendis Pharma A/S | Halozyme Therapeutics Inc. |
| Country/Region | Denmark | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 16.90 billion USD | 11.81 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | January 28, 2015 | March 16, 2004 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ASND | HALO |
|---|---|---|
| Total Return (1Y) | 29.46% | 50.94% |
| Total Return (3Y, Annualized) | 40.62% | 41.08% |
| Total Return (5Y, Annualized) | 10.03% | 21.68% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ASND | HALO |
|---|---|---|
| Volatility (1Y, Annualized) | 38.62% | 41.19% |
| Beta (5Y) | 0.38 | 0.96 |
| Max Drawdown (5Y) | -55.93% | -49.06% |
| Avg. Volume (3M) | 698.39K | 2.29M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ASND | HALO |
|---|---|---|
| Sharpe Ratio (1Y) | 0.65 | 1.13 |
| Sortino Ratio (1Y) | 0.99 | 1.78 |
Profitability
ROE (TTM)
Both Ascendis Pharma (ASND) at 118.78% and Halozyme Therapeutics (HALO) at 216.38% turn shareholders’ equity into profit at rates above their industry benchmark ranges for ROE. That is a strong capital-efficiency signal, though leverage and the equity base still matter.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
118.78%
- ASND
- 118.78%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
216.38%
- HALO
- 216.38%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both Ascendis Pharma (ASND) at 70.85% and Halozyme Therapeutics (HALO) at 26.93% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
70.85%
- ASND
- 70.85%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.93%
- HALO
- 26.93%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Ascendis Pharma (ASND) at 64.98% and Halozyme Therapeutics (HALO) at 59.84% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
64.98%
- Max
- 83.12%
- ASND
- 64.98%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
59.84%
- Max
- 83.12%
- HALO
- 59.84%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ASND | HALO |
|---|---|---|
| ROE (TTM) | 118.78% | 216.38% |
| ROA (TTM) | 9.58% | 22.42% |
| Net Margin (TTM) | 70.85% | 26.93% |
| Operating Margin (TTM) | 64.98% | 59.84% |
| Gross Margin (TTM) | 91.30% | 77.74% |
Growth
Revenue Growth
Ascendis Pharma (ASND) at 98.03% sits in the top revenue growth quartile, while Halozyme Therapeutics (HALO) at 37.55% is closer to the peer norm — faster top-line expansion for ASND.
EPS Growth
Only one side can be read here: Halozyme Therapeutics (HALO) reports EPS growth of -25.36%, ranked against its industry; Ascendis Pharma (ASND) has no EPS growth figure this period.
Growth Metrics
| Metric | ASND | HALO |
|---|---|---|
| Revenue Growth (YoY) | 98.03% | 37.55% |
| Revenue Growth (3Y CAGR) | 141.43% | 28.38% |
| EPS Growth (YoY) | -- | -25.36% |
| EPS Growth (3Y CAGR) | -- | 21.14% |
Financial Strength
Current Ratio (MRQ)
Both Ascendis Pharma (ASND) at 2.99 and Halozyme Therapeutics (HALO) at 3.88 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.99
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ASND
- 2.99
- Q1
- 2.47
- Min
- 0.10
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.88
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- HALO
- 3.88
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Only one side’s leverage can be read here: Ascendis Pharma (ASND) carries debt-to-equity ratio of 0.31 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.31
- Max
- 1.42
- Q3
- 0.65
- ASND
- 0.31
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- HALO
- --
Financial Strength Metrics
| Metric | ASND | HALO |
|---|---|---|
| Current Ratio (MRQ) | 2.99 | 3.88 |
| Debt / Equity (MRQ) | 0.31 | -- |
| Net Debt / EBITDA | -1.37 | 1.90 |
Dividends
Dividend Yield (TTM)
Neither Ascendis Pharma (ASND) nor Halozyme Therapeutics (HALO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ASND
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- HALO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Ascendis Pharma (ASND) nor Halozyme Therapeutics (HALO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ASND
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- HALO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ASND | HALO |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Both Ascendis Pharma (ASND) at 19.68 and Halozyme Therapeutics (HALO) at 25.91 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.68
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- ASND
- 19.68
- Q1
- 13.30
- Min
- 0.07
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.91
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- HALO
- 25.91
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Ascendis Pharma (ASND) at 16.14 and Halozyme Therapeutics (HALO) at 6.55 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.14
- Max
- 58.18
- Q3
- 25.77
- ASND
- 16.14
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.55
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- HALO
- 6.55
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Ascendis Pharma (ASND) reports 10.45, ranking against industry peers normally.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.45
- Max
- 13.53
- ASND
- 10.45
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-213.67
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
- HALO
- -213.67
Valuation Metrics
| Metric | ASND | HALO |
|---|---|---|
| P/E Ratio (TTM) | 19.68 | 25.91 |
| P/S Ratio (TTM) | 16.14 | 6.55 |
| P/B Ratio (MRQ) | 10.45 | -213.67 |
| Free Cash Flow Yield (TTM) | 0.08% | 3.48% |